The United Kingdom and the United States have announced a significant trade agreement that will keep no import taxes on British medicine products being sold in the American market.
Key Provisions of the Deal
As part of the deal, the UK has agreed to increase funding on drugs through the National Health Service (NHS). This pledge guarantees that import taxes on these key exports will stay at zero for a duration of three years.
This development follows recent warnings to hike duties on patented pharmaceutical imports, with increases floated up to one hundred percent.
"This deal with the United Kingdom reinforces the worldwide climate for innovative medicines and introduces long-overdue equity to U.S.–U.K. pharmaceutical trade," a statement said.
Commercial Impact
Pharmaceuticals represent one of the the United Kingdom's biggest goods shipped to the United States, which is easily the largest market for leading companies like GSK and AstraZeneca.
Trade data reveal that in the 12 months to the end of the third quarter, the UK shipped medicines valued at billions to the US. This value represented a significant portion of total UK exports in that period.
"This guarantee protects jobs, stimulates capital expenditure and sets the stage for the UK to emerge as a global hub for biotech and pharma," the Business and Trade Secretary remarked.
Detailed British Pledges
The deal entails several specific pledges from the British government:
- Higher Cost Ceiling: The UK will lift the cost ceiling at which it judges new treatments to be unaffordable by twenty-five percent.
- Increased NHS Spending: There is a aim to double overall health service expenditure on drugs from 0.3 percent of GDP to 0.6 percent over the following ten-year period.
- Refund Ceiling: The sum pharmaceutical firms must refund to the NHS to stay within budget will be capped at 15%. Previously, refunds topped 20%.
Recent Tensions
The pact takes place against a long-running row between the drug companies and the ministers over medicine costs and NHS adoption.
This friction were intensified by assertions that US consumers were charged several times more for the equivalent treatments than patients in the UK and Europe.
Over the last 18 months, several significant drug company projects in the UK have been halted or cancelled, while substantial expansions have been announced toward US facilities.
A senior figure stated that the NHS had to spend more on drugs, noting that its spending on drugs had shrunk as a percentage of its overall budget over the last ten years.